BioPharmSignal logoBioPharmSignal

Biotech News

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

Nurix Therapeutics (NRIX)Nurix TherapeuticsCompany update

Accomplished human resources executive brings more than 20 years of leadership experience building high-performing organizations through clinical development and commercialization BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.

Related news

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

BNTXBioNTech2026-08-03 09:00 EST

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

GERNGeron2026-07-13 12:00 EST

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

KYMRKymera2026-06-24 20:01 EST

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

GPCRStructure Therapeutics2026-06-05 20:05 EST

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

View all latest news

Nurix Therapeutics

Targeted Protein Degradation Nurix Therapeutics develops medicines that use the cell’s ubiquitin-proteasome system to remove disease-causing proteins. Its portfolio includes wholly owned degraders and programs partnered with large pharmaceutical companies. Bexobrutideg Bexobrutideg is an oral BTK degrader being advanced as a potential...

Recent company news

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
26.72 USD
Market cap
1.69B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States